• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Mercy BioAnalytics Appoints Dawn Mattoon, PhD, as Chief Operating Officer

    7/11/22 8:00:00 AM ET
    $QTRX
    $TMO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Industrial Machinery/Components
    Industrials
    Get the next $QTRX alert in real time by email

    Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the appointment of experienced biotechnology executive, Dawn Mattoon, PhD, as Chief Operating Officer, effective today. In her nearly 20-year career, Dr. Mattoon has developed and commercialized a broad range of innovative proteomic and genomic technologies.

    Dr. Mattoon possesses a proven track record of delivering top and bottom-line growth as a leader in research and development, strategy, and general management for companies such as Invitrogen, Life Technologies, Thermo Fisher Scientific Inc. (NYSE:TMO), and Cell Signaling Technologies. Most recently, Dr. Mattoon served as Senior Vice President of Clinical Diagnostics at Quanterix Corporation (NASDAQ:QTRX), where she led the development and commercialization of the company's first FDA-authorized diagnostic tests for COVID-19 and received FDA Breakthrough Device designations for diagnostic tests addressing Alzheimer's Disease and Multiple Sclerosis. She holds a PhD in molecular genetics from Yale University, where she also completed her postdoctoral fellowship.

    "We are humbled to welcome Dr. Mattoon to the Mercy family at an important moment in our drive towards global commercialization of our powerful Mercy Halo™ early cancer detection test platform. The clinical studies of our technology in ovarian and lung cancer presented recently at the American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO) conferences provide promising evidence of the diagnostic potential of this approach, and we are excited that Dr. Mattoon shares our passion for our mission to relieve suffering and save lives through the early detection of cancer," said Mercy BioAnalytics CEO Paul Blavin. "We look forward to benefitting from her experience as she assumes her role overseeing Mercy's expanding business footprint, including scientific, clinical, and commercial operations."

    "Mercy is bringing a highly differentiated approach to the early detection of cancer and has assembled a world-class network of colleagues, collaborators, and partners to deliver on the vision of improving the lives of cancer patients and their families," said Dr. Mattoon. "I have a passion for building businesses based on impactful, innovative clinical products, and am thrilled to be part of a company with such tremendous potential to benefit the global community."

    Read a recent profile on Mercy BioAnalytics published by GenomeWeb here.

    ABOUT MERCY BIOANALYTICS

    Mercy BioAnalytics, Inc. is on a mission to relieve suffering and save lives through the early detection of cancer. Early-stage cancer is difficult to detect, but when found, is more often amenable to curative therapy. The patented Mercy Halo™ liquid biopsy platform utilizes biomarker co-localization to interrogate highly abundant blood-based extracellular vesicles that carry unique cancer signatures from their parent cells. The Mercy Halo™ platform is designed to detect stage I cancer, when it is most treatable, and enhance the quality of life for cancer patients and their families. Mercy's initial focus is the early detection of ovarian and lung cancers. Ovarian cancer, the most lethal gynecological cancer, typically goes undetected until it is too late to cure. Lung cancer, the number-one cancer killer, takes more lives than breast, prostate, and colorectal cancers combined. For additional information, please visit https://www.mercybio.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005164/en/

    Get the next $QTRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $QTRX
    $TMO

    CompanyDatePrice TargetRatingAnalyst
    Thermo Fisher Scientific Inc
    $TMO
    1/10/2025$630.00Mkt Perform → Outperform
    Bernstein
    Thermo Fisher Scientific Inc
    $TMO
    12/23/2024Sector Perform
    Scotiabank
    Thermo Fisher Scientific Inc
    $TMO
    10/14/2024Buy
    Redburn Atlantic
    Thermo Fisher Scientific Inc
    $TMO
    10/1/2024$680.00Overweight
    Stephens
    Thermo Fisher Scientific Inc
    $TMO
    8/28/2024$670.00Overweight
    Wells Fargo
    Thermo Fisher Scientific Inc
    $TMO
    6/3/2024$650.00Buy
    Jefferies
    Thermo Fisher Scientific Inc
    $TMO
    3/18/2024$620.00Neutral
    Citigroup
    Quanterix Corporation
    $QTRX
    2/1/2024$30.00Sector Outperform
    Scotiabank
    More analyst ratings

    $QTRX
    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/13/25 4:39:15 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/10/25 4:08:44 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Walt David R bought $1,133,796 worth of shares (210,000 units at $5.40), increasing direct ownership by 14% to 1,706,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/9/25 5:44:04 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 23, 2025

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2025 before the market opens on Wednesday, July 23, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 523661. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under t

      7/1/25 8:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Quanterix Expands Reach with IVD and Large Reference Labs

      Simoa Technology Advances Earlier Disease Detection by Measuring Signature Biomarkers Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration by the Ministry of Food and Drug Safety (MFDS) in South Korea through its regional distribution partner, HS Biosystems. The continued expansion of the industry-leading Simoa® technology platform into global markets demonstrates a key milestone in broadening validation of biomarker-based testing and providing clinicians with minimally invasive tools that can help enhance diagnostic

      6/23/25 7:30:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 908 Devices Appoints Christopher D. Brown to its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

      6/16/25 8:00:00 AM ET
      $AAPL
      $MASS
      $RGEN
      $TMO
      Computer Manufacturing
      Technology
      Industrial Machinery/Components
      Industrials

    $QTRX
    $TMO
    Leadership Updates

    Live Leadership Updates

    See more
    • 908 Devices Appoints Christopher D. Brown to its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

      6/16/25 8:00:00 AM ET
      $AAPL
      $MASS
      $RGEN
      $TMO
      Computer Manufacturing
      Technology
      Industrial Machinery/Components
      Industrials
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components

    $QTRX
    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Quanterix Corporation

      SC 13G/A - Quanterix Corp (0001503274) (Subject)

      11/13/24 12:41:46 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Quanterix Corporation

      SC 13G - Quanterix Corp (0001503274) (Subject)

      6/27/24 2:46:59 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Quanterix Corporation (Amendment)

      SC 13G/A - Quanterix Corp (0001503274) (Subject)

      2/14/24 4:57:53 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Thermo Fisher upgraded by Bernstein with a new price target

      Bernstein upgraded Thermo Fisher from Mkt Perform to Outperform and set a new price target of $630.00

      1/10/25 8:42:46 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Scotiabank initiated coverage on Thermo Fisher

      Scotiabank initiated coverage of Thermo Fisher with a rating of Sector Perform

      12/23/24 8:24:48 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Redburn Atlantic initiated coverage on Thermo Fisher

      Redburn Atlantic initiated coverage of Thermo Fisher with a rating of Buy

      10/14/24 9:24:58 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $QTRX
    $TMO
    SEC Filings

    See more
    • Quanterix Corporation filed SEC Form 8-K: Shareholder Director Nominations, Other Events, Financial Statements and Exhibits

      8-K - Quanterix Corp (0001503274) (Filer)

      7/1/25 4:10:53 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 11-K filed by Thermo Fisher Scientific Inc

      11-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

      6/17/25 2:30:55 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form EFFECT filed by Quanterix Corporation

      EFFECT - Quanterix Corp (0001503274) (Filer)

      6/13/25 12:15:03 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hlavinka Sarah E. was granted 2,615 shares, increasing direct ownership by 5% to 60,070 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      7/3/25 2:37:32 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Meister Paul M was granted 2,242 shares, increasing direct ownership by 0.73% to 309,279 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      7/2/25 5:39:38 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Donnelly William P was granted 4,204 shares, increasing direct ownership by 3% to 143,298 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      7/2/25 5:37:17 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    $TMO
    Financials

    Live finance-specific insights

    See more
    • Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 23, 2025

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2025 before the market opens on Wednesday, July 23, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 523661. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under t

      7/1/25 8:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Declares Quarterly Dividend

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on July 15, 2025, to shareholders of record as of June 13, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the developmen

      5/21/25 4:15:00 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Quanterix Releases Financial Results for the First Quarter of 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward," said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new early-access program, Simoa® ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide—significantly reducing the need for capital equipment purchases by current and future customers. This leap is enabled by

      5/12/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials